Longevica Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
7
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$175K
- Investors
-
4
Longevica General Information
Description
Developer of an end-to-end healthy aging platform intended to improve health and quality of life and prevent age-related disease. The company offers new revenue streams to hospitals and clinics, empowering physicians and nurses to deliver complex clinical programs in an efficient, scalable, personalized, and timely manner, and also approach brings the right care to achieve better patient outcomes, enabling customers to live healthier and longer lives.
Contact Information
Website
longevica.com(Operating Subsidiary)
Corporate Office
- 640 Masonic Way MS150
- Belmont, CA 94002
- United States
Corporate Office
- 640 Masonic Way MS150
- Belmont, CA 94002
- United States
Longevica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 16-Sep-2022 | $175K | Completed | Clinical Trials - General | ||
| 5. Later Stage VC | 24-Nov-2021 | Completed | Clinical Trials - General | |||
| 4. Grant | 10-Jun-2015 | Completed | Product Development | |||
| 3. Grant | 01-Jan-2014 | Completed | Product Development | |||
| 2. Merger/Acquisition | 27-Jul-2010 | $13M | Completed | Product Development | ||
| 1. Early Stage VC | 24-Nov-2008 | $13M | $13M | Completed | Product Development |
Longevica Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Longevica Patents
Longevica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10106552-B2 | Compounds inhibiting eukaryotic elongation factor 2 kinase activity | Active | 13-Nov-2013 | ||
| US-20160318948-A1 | Compounds inhibiting eukaryotic elongation factor 2 kinase activity | Active | 13-Nov-2013 | ||
| WO-2015102752-A1 | Compounds inhibiting eukaryotic elongation factor 2 kinase activity | Inactive | 13-Nov-2013 | C07D495/04 |
Longevica Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Longevica Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Foundation Venture Capital Group | Venture Capital | Minority |
Longevica FAQs
-
When was Longevica founded?
Longevica was founded in 2008.
-
Where is Longevica headquartered?
Longevica is headquartered in Belmont, CA.
-
What is the size of Longevica?
Longevica has 7 total employees.
-
What industry is Longevica in?
Longevica’s primary industry is Monitoring Equipment.
-
Is Longevica a private or public company?
Longevica is a Private company.
-
What is Longevica’s current revenue?
The current revenue for Longevica is .
-
How much funding has Longevica raised over time?
Longevica has raised $2.67M.
-
Who are Longevica’s investors?
Foundation Venture Capital Group has invested in Longevica.
-
When was Longevica acquired?
Longevica was acquired on 16-Sep-2022.
-
Who acquired Longevica?
Longevica was acquired by Rostock Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
